Changes in Biomarkers of Coagulation, Fibrinolytic, and Endothelial Functions for Evaluating the Predisposition to Venous Thromboembolism in Patients With Hereditary Thrombophilia

Li, Lei; Gao, Lixia; Wu, Xi; Wu, Wenman; Ding, Qiulan; Wang, Xuefeng

doi:10.1177/1076029620944471

Cited by 2 publications

(2 citation statements)

References 29 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…These results were in full agreement with the results reported by Zhou et al [17] ROC curve analysis showed that the AUC values of the thrombosis-related biomarkers were lower than the AUC values of the d-dimer and FDP, but their diagnostic speci city was higher. D-dimer and FDP were removed because of multicollinearity in the multivariate analysis.…”

Section: Comparison Of Diagnostic E Cacy Between the New Risk Predict...supporting

confidence: 92%

“…Secondly, the secretion of t-PAIC is time-dependent. [17] However, collection of blood specimens was based on the clinical need and may have affected the diagnostic e cacy. Finally, we did not further investigate the anticoagulation regimen in lung cancer patients with concomitant thrombosis.…”

Section: Comparison Of Diagnostic E Cacy Between the New Risk Predict...mentioning

confidence: 99%

See 1 more Smart Citation

Early identification of lung cancer patients with venous thromboembolism: development and validation of a risk prediction model

Ling

et al. 2023

Preprint

View full text Add to dashboard Cite

Introduction: Venous thromboembolism(VTE) is a leading cause of death in patients with lung cancer. Furthermore, hospitalization of patients with advanced lung cancer for VTE treatment represents a major economic burden on the national public health resources. Therefore, we performed this prospective study to identify clinical biomarkers for the early identification of VTE in lung cancer patients. Methods: This prospective study enrolled 158 patients with confirmed lung cancer, including 27 who were diagnosed with VTE within six months of the follow-up after lung cancer diagnosis. Multivariate logistic regression analysis was used to evaluate the diagnostic performancese of all the relevant clinical features and laboratory indicators in identifying lung cancer patients with a higher risk of VTE. A novel risk prediction model was constructed consisting of five clinical variables with the best diagnostic performances and was validated using the receiver operation characteristic(ROC) curves. The diagnostic performances of the new risk prediction model was also compared with the Khorana risk score (KRS) and the Padua risk score (PRS). Results: The VTE group of lung cancer patients (n = 27) showed significantly higher serum levels of fibrin degradation products (FDP), D-dimer, thrombomodulin (TM), thrombin-antithrombin-complex (TAT), α2-plasmin inhibitor-plasmin Complex (PIC), and tissue plasminogen activator-plasminogen activator inhibitor complex (t-PAIC) compared to those in the non-VTE group (n = 131). ROC curve analyses showed that the diagnostic efficacy of the new VTE risk prediction model with TM ≥ 9.75 TU/ml, TAT ≥ 2.25ng/ml, t-PAIC ≥ 7.35ng/ml, history of VTE, and ECOG PS score ≥ 2 was superior than the KRS and the PRS in the early identification of lung cancer patients with a higher risk of VTE. Conclusions: The new risk prediction model showed significantly high diagnostic efficacy in the early identification of lung cancer patients with a high risk of VTE. The diagnostic efficacy of the new risk prediction model was higher than the KRS and the PRS in this cohort of lung cancer patients.

show abstract

Section: Comparison Of Diagnostic E Cacy Between the New Risk Predict...supporting

confidence: 92%

Section: Comparison Of Diagnostic E Cacy Between the New Risk Predict...mentioning

confidence: 99%

Early identification of lung cancer patients with venous thromboembolism: development and validation of a risk prediction model

Ling

et al. 2023

Preprint

View full text Add to dashboard Cite

show abstract

Early identification of lung cancer patients with venous thromboembolism: development and validation of a risk prediction model

Di,

Xu,

Ling

et al. 2023

Thrombosis J

View full text Add to dashboard Cite

Introduction Venous thromboembolism(VTE) is a leading cause of death in patients with lung cancer. Furthermore, hospitalization of patients with advanced lung cancer for VTE treatment represents a major economic burden on the national public health resources. Therefore, we performed this prospective study to identify clinical biomarkers for the early identification of VTE in lung cancer patients. Methods This prospective study enrolled 158 patients with confirmed lung cancer, including 27 who were diagnosed with VTE within six months of the follow-up after lung cancer diagnosis. Multivariate logistic regression analysis was used to evaluate the diagnostic performancese of all the relevant clinical features and laboratory indicators in identifying lung cancer patients with a higher risk of VTE. A novel risk prediction model was constructed consisting of five clinical variables with the best diagnostic performances and was validated using the receiver operation characteristic(ROC) curves. The diagnostic performances of the new risk prediction model was also compared with the Khorana risk score (KRS) and the Padua risk score (PRS). Results The VTE group of lung cancer patients (n = 27) showed significantly higher serum levels of fibrin degradation products (FDP), D-dimer, thrombomodulin (TM), thrombin-antithrombin-complex (TAT), α2-plasmin inhibitor-plasmin Complex (PIC), and tissue plasminogen activator-plasminogen activator inhibitor complex (t-PAIC) compared to those in the non-VTE group (n = 131). ROC curve analyses showed that the diagnostic efficacy of the new VTE risk prediction model with TM ≥ 9.75 TU/ml, TAT ≥ 2.25ng/ml, t-PAIC ≥ 7.35ng/ml, history of VTE, and ECOG PS score ≥ 2 was superior than the KRS and the PRS in the early identification of lung cancer patients with a higher risk of VTE. Conclusions The new risk prediction model showed significantly high diagnostic efficacy in the early identification of lung cancer patients with a high risk of VTE. The diagnostic efficacy of the new risk prediction model was higher than the KRS and the PRS in this cohort of lung cancer patients.

show abstract

Changes in Biomarkers of Coagulation, Fibrinolytic, and Endothelial Functions for Evaluating the Predisposition to Venous Thromboembolism in Patients With Hereditary Thrombophilia

Cited by 2 publications

References 29 publications

Early identification of lung cancer patients with venous thromboembolism: development and validation of a risk prediction model

Early identification of lung cancer patients with venous thromboembolism: development and validation of a risk prediction model

Early identification of lung cancer patients with venous thromboembolism: development and validation of a risk prediction model

Contact Info

Product

Resources

About